Adicet Bio Inc
Follow $ACET
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ACET by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredsnapshot unavailable for ACET. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ACET moving today?
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ACET overview
Related filings and maps
Congress activity in ACET
No receipt-qualified Congressional disclosure is present for ACET in the cached public ledger.
ACET contract awards, year to date.
Public federal awards linked to this ticker.
ACET lobbying filings, year to date.
Registered lobbying filings matched to Adicet Bio Inc.